Clinical Trial Update: Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the efficacy and safety of a combination therapy—gemcitabine/cisplatin (GemCis) with trastuzumab and pembrolizumab—in pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Pembrolizumab (pembrolizumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Biliary Tract Cancer, HER2 Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING